Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
Sepsis and septic shock patients are considered to have a high risk of complications and
death. Appropriate antimicrobial therapy plays an important role in determining outcomes in
septic patients. However, pathophysiologic changes associated with critical illness have an
impact on pharmacokinetics of antimicrobials. In addition, increasing bacterial resistance is
also a growing concern, especially in intensive care units., Consequently, standard
antimicrobial dose may not be sufficient to achieve pharmacokinetic/pharmacodynamic target in
sepsis and septic shock patients. The purpose of this study is to compare a therapy between
meropenem standard dose and meropenem high dose in the treatment of sepsis and septic shock